Mauna Kea Technologies SAS represents a set of core values and a corporate philosophy that is deeply rooted in innovation, excellence, and patient-centricity. The company strives to revolutionize medical imaging and diagnostics by developing cutting-edge medical devices and technology solutions. Mauna Kea Technologies SAS is committed to improving patient outcomes by providing physicians with real-time, high-resolution imaging capabilities for a more accurate and precise diagnosis. The company also prioritizes ethical practices, sustainable development, and collaboration with healthcare professionals to advance the field of medical imaging. Mauna Kea Technologies SAS is dedicated to pushing boundaries and constantly striving for excellence in the healthcare industry.

Mauna Kea Technologies SAS is primarily present in several countries and regions globally. It has a significant presence in the United States, particularly in the New York City metropolitan area. In addition, the company operates extensively in Europe, with a strong presence in France, Germany, Italy, Spain, and the United Kingdom. Mauna Kea Technologies SAS also has a growing market share in the Asia-Pacific region, including Australia, China, Japan, and South Korea. With its widespread international presence, Mauna Kea Technologies SAS continues to expand its reach and impact in the field of medical technology and innovative imaging solutions.

Mauna Kea Technologies SAS has achieved several significant milestones throughout its history. The company introduced Cellvizio, a breakthrough endomicroscopy platform, which has transformed the way physicians diagnose and monitor diseases. The technology has gained widespread recognition and has been adopted by renowned medical institutions globally. Furthermore, Mauna Kea Technologies SAS secured regulatory approvals for its innovative products, strengthening its market position and expanding its customer base. The company's dedication to research and development has led to numerous patents and advancements in optical biopsy solutions. Overall, Mauna Kea Technologies SAS has consistently demonstrated its commitment to advancing medical imaging and improving patient care.

Mauna Kea Technologies SAS is a renowned medical technology company specializing in the development and commercialization of innovative optical biopsy products. Founded in 2000, the company has focused on revolutionizing the detection and treatment of cancer and other diseases through its proprietary Cellvizio® platform. Mauna Kea Technologies has successfully integrated high-resolution imaging and miniaturized endomicroscopy into its advanced devices, enabling physicians to perform real-time, in vivo microscopy during standard procedures. With a commitment to improving patient outcomes and advancing medical knowledge, Mauna Kea Technologies SAS continues to drive advancements in optical biopsy technology worldwide. Find out more about Mauna Kea Technologies SAS on our stock website.

The main competitors of Mauna Kea Technologies SAS in the market include companies such as Intuitive Surgical, Medtronic, Olympus Corporation, and Pentax Medical.

Mauna Kea Technologies SAS is primarily active in the medical industry, specifically in the field of innovative medical devices.

The business model of Mauna Kea Technologies SAS revolves around pioneering and delivering innovative endomicroscopy solutions. As a global medical device company, Mauna Kea specializes in developing and commercializing probe-based Confocal Laser Endomicroscopy (pCLE) technology. This enables real-time visualization of tissue at the cellular level during minimally invasive procedures. By combining advanced imaging capabilities with their Cellvizio platform, Mauna Kea enables medical professionals to improve patient care and treatment outcomes. Through strategic partnerships and commercialization efforts, the company aims to leverage its cutting-edge technologies to enhance diagnostic procedures and revolutionize healthcare practices worldwide.

Mauna Kea Technologies KGV ir -2,31.

Mauna Kea Technologies KUV ir 1,64.

AlleAktien kvalitātes vērtējums Mauna Kea Technologies ir 2/10.

gaidāmā Mauna Kea Technologies apgrozījums ir 11,02 milj. EUR.

gaidāmā Mauna Kea Technologies peļņa ir -7,85 milj. EUR.

Mauna Kea Technologies SAS is a French company that specializes in the development and marketing of medical devices and procedures that provide precise diagnostic and therapeutic solutions for various types of cancer. The company uses its patented technologies to develop applications for endoscopic imaging, fluorescence microscopy, and optical biopsy.

Mauna Kea Technologies izmaksā dividendes 0 EUR, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Mauna Kea Technologies vai uzņēmums nedod dividendes.

Mauna Kea Technologies ISIN ir FR0010609263.

Mauna Kea Technologies WKN ir A1JCLA.

Mauna Kea Technologies simbols ir ALMKT.PA.

Pēdējo 12 mēnešu laikā Mauna Kea Technologies maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Mauna Kea Technologies plāno maksāt dividendes 0 EUR apmērā.

Mauna Kea Technologies pašreizējā dividendu rentabilitāte ir .

Mauna Kea Technologies maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Mauna Kea Technologies pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 EUR. Tas atbilst dividendes ražībai 0 %.

Mauna Kea Technologies tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Mauna Kea Technologies apmērā 0 EUR, kas tika izmaksāta 18.08.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 18.08.2024..

Pēdējās dividendes izmaksa notika 18.08.2024..

Gadā 2023, Mauna Kea Technologies izmaksāja 0 EUR dividendes.

Mauna Kea Technologies dividendes tiek izmaksātas EUR.